Skip to main content
. 2020 Mar 2;4:19. doi: 10.1186/s41927-020-0118-z

Fig. 1.

Fig. 1

Physician-reported reasons given for patient switching from 1st to 2nd line TNFi. * Secondary lack of efficacy: loss of response over time; † I wanted to use bDMARD that can be used as a monotherapy; ‡ I wanted to use a bDMARD that can be used in combination. MOA: Mode of action; bDMARD: biologic Disease Modifying Anti Rheumatic Drug